论文部分内容阅读
目的 :评价普伐他汀对内皮依赖性血管舒张功能的影响。方法 :对 5 8例冠心病 (CHD)患者 (A组 )及 30例健康人 (B组 )采用高分辨血管外超声技术测定肱动脉血流介导的舒张功能及硝酸甘油介导的舒张功能。A组服普伐他汀 6个月后复查。结果 :A组肱动脉血流介导的舒张及硝酸甘油介导的舒张均低于B组 [分别为(2 .85± 2 .77) %∶(8.14± 3.6 5 ) %、(16 .6 8± 5 .71) %∶(2 4 .83± 6 .79) % ,均P <0 .0 1],A组治疗后较治疗前明显好转 [分别为 (6 .4 5± 3.82 ) %∶(2 .85± 2 .77) %、(2 2 .4 6± 6 .37) %∶(16 .6 8± 5 .71) % ,均 P <0 .0 1]。结论 :普伐他汀对CHD患者受损的内皮依赖性舒张功能有较好的治疗价值 ,与其非调脂作用有关
AIM: To evaluate the effect of pravastatin on endothelium-dependent vasodilation. Methods: Fifty-eight CHD patients (group A) and 30 healthy volunteers (group B) were measured by high-resolution extracorporeal ultrasonography of brachial artery blood flow-mediated diastolic function and nitroglycerin-mediated diastolic function . A group of pravastatin 6 months after the review. Results: The brachial artery-mediated diastolic and nitroglycerin-mediated diastolic velocities in group A were significantly lower than those in group B [(2.85 ± 2 .77)% vs (8.14 ± 3.6 5)%, (16.6 8 ± 5 .71)% (2 4 .83 ± 6 .79)%, all P <0 01]. The A group was significantly better than that before treatment [(6.44 ± 3.82)% (2 .85 ± 2 .77)%, (22.4 ± 6 .37)%: (16.6 ± 5 .71)%, all P <0. Conclusion: Pravastatin has better therapeutic value on the impaired endothelium-dependent diastolic function in CHD patients, which is related to its non-lipid-lowering effect